Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

diclofenacsodium 1%, linseed oil 3%, methylsalicylate 10%, menthol 5%

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - diclofenac sodium - gel - 1 percent weight/weight - diclofenac

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - diclofenac sodium - gel - 2 percent weight/weight - diclofenac

United States - English - NLM (National Library of Medicine)

advagen pharma ltd - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation). diclofenac sodium delayed-release tablets are indicated: • for relief of the signs and symptoms of osteoarthritis • for relief of the signs and symptoms of rheumatoid arthritis • for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets are contraindicated in the following patients: • known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions). • history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaid